Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1+PD-1 Monoclonal Antibody in Triple-negative Breast Cancer
NCT06471205Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of izalontamab brengitecan in triple-negative breast cancer (TNBC), sponsored by Biokin Pharmaceutical. Primary endpoints: Objective Response Rate at 24 months and Recommended Phase II Dose at 24 months. Started Aug 2024; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06471205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06471205.